Please login to the form below
BioMarin
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of BioMarin's 2012 metabolic sales performance.
Novo Nordisk, bluebird team up to develop haemophilia A therapies
BioMarin and uniQure are also working on haemophilia A gene therapies.
NICE approves BioMarin’s Brineura after initial setback
However, the therapy has now been approved in the context of a managed access agreement between BioMarin and the cost-effectiveness watchdog. ... However, it is likely that BioMarin will have had to make a concession on price to reach an agreement.
Roche’s Hemlibra scores broader NHS funding
BioMarin is in pole position with its candidate valrox, which it plans to submit by the end of 2019.
BioMarin ticks over in Q2 ahead of gene therapy filing
Jean-Jacques Bienaimé, chief executive officer of BioMarin commented:. Jean-Jacques Bienaimé, CEO, BioMarin. ... BioMarin will also hope to extend the commercial success of Brineura, its Batten disease therapy.
Roche reveals yet another Spark takeover delay
Analysts at Jefferies have suggested that is unlikely to be the case, given that a number of other companies are developing haemophilia gene therapies including BioMarin, Sangamo and UniQure which all
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
-
Senior Copywriter
-
Salary TBC
- Senior / Principal Medical Writers wanted - MedComms - Various U...
-
Excellent Remuneration Packages
- Senior Account Manager / Account Director - MedComms - London
-
Highly competitive salary &package
- Experienced / Senior Medical Writer - Excellent Progression Oppo...
-
Excellent Salary and Benefits on offer
-
Senior Medical Writer
-
Salary TBC
- Editorial Assistants - Medical Communications agency - Cheshire
-
Excellent Remuneration Package
-
Account Director, Medical Education
-
Salary TBC
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Medical Writer – Medical Communications – North West – In...
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Competitive salary plus benefits
Subscribe to our email news alerts
- Leading AstraZeneca’s return to growth in Europe
- Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
- GSK forms cell therapy R&D pact with star-studded biotech
- Bayer/J&J claim new FDA okay for clot drug Xarelto
- Allergan investors back AbbVie deal, but is a tax charge looming?
- Bayer opens AI-enabled drug discovery center in UK
- Spotlight interview: 15 minutes on PR in pharma
- Changing healthcare, one film at a time
- Faisal Ahmed joins healthcare comms agency Sudler London
- Red Consultancy appoints MD in its health division
- Takeda offloads select portfolio to Acino ahead of Shire takeover
- Wilmington Healthcare appoints new consultants
PMHub
Kendle Healthcare
Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...
Latest intelligence
- eyeforpharma Marketing and Customer Innovation Europe
- By Richard Springham...
- The Golden Goose
- Why it’s so hard for the US to curb runaway drug prices...
- What is changing in cardiovascular disease care?
- Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
Quick links
Infographics
